{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:12:40Z","timestamp":1789053160135,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the endocrine society of India","award":["#2017008"],"award-info":[{"award-number":["#2017008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12664-021-01176-6","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:02:33Z","timestamp":1640311353000},"page":"556-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"40","author":[{"given":"P Ganavi","family":"Yamasandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Dharmalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Balekuduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,24]]},"reference":[{"key":"1176_CR1","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u201323.","DOI":"10.1002\/hep.25762"},{"key":"1176_CR2","doi-asserted-by":"crossref","unstructured":"Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844\u201350.","DOI":"10.2337\/diabetes.50.8.1844"},{"key":"1176_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221\u201331.","journal-title":"N Engl J Med"},{"key":"1176_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/qjmed\/hct198","volume":"107","author":"MJ Armstrong","year":"2014","unstructured":"Armstrong MJ, Hazlehurst JM, Parker R, et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM. 2014;107:33\u201341.","journal-title":"QJM"},{"key":"1176_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.dsx.2014.09.009","volume":"9","author":"A Esteghamati","year":"2015","unstructured":"Esteghamati A, Afarideh M, Feyzi S, Noshad S, Nakhjavani M. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes Metab Syndr. 2015;9:258\u201365.","journal-title":"Diabetes Metab Syndr"},{"key":"1176_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/2230-8210.146874","volume":"19","author":"M Gutch","year":"2015","unstructured":"Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity\/resistance. Indian J Endocrinol Metab. 2015;19:160\u20134.\u00a0","journal-title":"Indian J Endocrinol Metab"},{"key":"1176_CR7","doi-asserted-by":"crossref","unstructured":"Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology. 2012;153:2974\u201384.\u00a0","DOI":"10.1210\/en.2011-2043"},{"key":"1176_CR8","doi-asserted-by":"crossref","unstructured":"Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012;18:1279\u201385.","DOI":"10.1038\/nm.2851"},{"key":"1176_CR9","doi-asserted-by":"crossref","unstructured":"Stefan N, Sun Q, Fritsche A, et al. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: prospective cohort- and cross-sectional phenotyping studies. PLoS One. 2014;9:e92238.","DOI":"10.1371\/journal.pone.0092238"},{"key":"1176_CR10","doi-asserted-by":"crossref","unstructured":"Stefan N, Hennige AM, Staiger H, et al. Fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006;29:853\u20137.","DOI":"10.2337\/diacare.29.04.06.dc05-1938"},{"key":"1176_CR11","doi-asserted-by":"crossref","unstructured":"Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, Chang CJ. Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf). 2011;75:450\u20135.","DOI":"10.1111\/j.1365-2265.2011.04070.x"},{"key":"1176_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2014.08.041","volume":"62","author":"VW Wong","year":"2015","unstructured":"Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62:182\u20139.","journal-title":"J Hepatol"},{"key":"1176_CR13","unstructured":"Prasetya IB, Hasan I, Wisnu W, Rumende CM. Prevalence and profile of fibrosis in diabetic patients with non-alcoholic fatty liver disease and the associated factors. Acta Med Indones. 2017;49:91-8.\u00a0"},{"key":"1176_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1210\/er.2008-0009","volume":"29","author":"N Stefan","year":"2008","unstructured":"Stefan N, Kantartzis K, H\u00e4ring HU. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29:939\u201360.","journal-title":"Endocr Rev"},{"key":"1176_CR15","doi-asserted-by":"crossref","unstructured":"Yilmaz Y, Yonal O, Kurt R, et al. Serum fetuin-A\/a2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010;47:549\u201353.","DOI":"10.1258\/acb.2010.010169"},{"key":"1176_CR16","doi-asserted-by":"publisher","first-page":"107149","DOI":"10.18632\/oncotarget.22361","volume":"8","author":"Z Cui","year":"2017","unstructured":"Cui Z, Xuan R, Yang Y. Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population. Oncotarget. 2017;8:107149\u201356.","journal-title":"Oncotarget."},{"key":"1176_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.26698","volume":"59","author":"L Yang","year":"2013","unstructured":"Yang L, Roh YS, Song J, et al. Transforming growth factor-beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2013;59:483\u201395.","journal-title":"Hepatology."},{"key":"1176_CR18","doi-asserted-by":"publisher","first-page":"e1517","DOI":"10.1097\/MD.0000000000001517","volume":"94","author":"Y Huang","year":"2015","unstructured":"Huang Y, Huang X, Ding L, et al. Serum Fetuin-A associated with fatty liver index, early indicator of nonalcoholic fatty liver disease: A strobe-compliant article. Medicine (Baltimore). 2015;94:e1517.","journal-title":"Medicine (Baltimore)"},{"key":"1176_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/ijem.IJEM_31_18","volume":"22","author":"SA Mondal","year":"2018","unstructured":"Mondal SA, Dutta D, Kumar M, et al. Neck circumference to height ratio is a reliable predictor of liver stiffness and nonalcoholic fatty liver disease in prediabetes. Indian J Endocr Metab. 2018;22:347\u201354.","journal-title":"Indian J Endocr Metab"},{"key":"1176_CR20","doi-asserted-by":"crossref","unstructured":"Peter A, Kovarova M, Staiger H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am J Physiol Endocrinol Metab. 2018;314:E266\u201373.","DOI":"10.1152\/ajpendo.00262.2017"},{"key":"1176_CR21","doi-asserted-by":"crossref","unstructured":"Haukeland JW, Dahl TB, Yndestad A, et al. Fetuin-A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2012;166:503\u201310.","DOI":"10.1530\/EJE-11-0864"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12664-021-01176-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-021-01176-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T05:08:11Z","timestamp":1643778491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12664-021-01176-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1007\/s12664-021-01176-6","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PGY, MD, and AB declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed conforming to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Sixty NDD were included in the study after the ethics committee approval and written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors are solely responsible for the data and the contents of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology\u00a0or the printer\/publishers are responsible for the results\/findings and content of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}